Molecular prognostic factors in patients with pancreatic cancer

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 12, 2007, Pages 1553-1569

  Tonini, Giuseppe ^a   Pantano, Francesco ^a   Vincenzi, Bruno ^a   Gabbrielli, Armando ^b   Coppola, Roberto ^b   Santini, Daniele ^a  

^a Department of Endoscopy ^*  (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Genes; Outcome; Pancreatic cancer; Prognosis; Protein; Survival

Indexed keywords

ADAM PROTEIN; ADAM PROTEIN 9; BEVACIZUMAB; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DYSADHERIN; ERLOTINIB; GEMCITABINE; GROWTH FACTOR; K RAS PROTEIN; MARIMASTAT; MATRILYSIN; MATRIX METALLOPROTEINASE; MICROSOMAL AMINOPEPTIDASE; MUCIN 4; PIGMENT EPITHELIUM DERIVED FACTOR; PLACEBO; PROTEIN BCL 2; PROTEIN BNIP3; PROTEIN P16; PROTEIN P53; SMAD4 PROTEIN; SURVIVIN; SYNDECAN 1; THROMBOPLASTIN; THROMBOSPONDIN 1; TIPIFARNIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; CAUSE OF DEATH; CELL INTERACTION; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; MONOTHERAPY; NONHUMAN; ONCOGENE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PROGNOSIS; PROTEIN FUNCTION; RASH; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 37349008544     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.12.1553     Document Type: Review

References (165)

1. PARKIN DM, BRAY FI, DEVESA SS: Cancer burden in the year 2000. The global picture. Eur. J. Cancer (2001) 37:4-66.
2. JEMAL A, MURRAY T, SAMUELS A et al.: Cancer statistics, 2003. CA Cancer J. Clin. (2003) 53:5-26.
3. SENER S, FRENGEN A, MENCK HR, WINCHESTER DP: Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National cancer database. J. Am. Coll. Surg. (1999) 189:1-7.
4. WEINBERG RA: Oncogenes, antioncogenes and the molecular basis of multistep carcinogenesis. Cancer Res. (1989) 49:3713-3719.
5. PILLAI R: Oncogenes and oncoproteins as tumor markers. Eur. J. Surg. Oncol. (1992) 18:417-424.
6. WEINBERG RA: Tumor suppressor genes. Science (1991) 254:1138-1142.
7. SKUSE GR, LUDLOW JW: Tumor suppressor genes in disease and therapy. Lancet (1995) 345:902-906.
8. KIRSCH DG, KASTAN MB: Tumor-suppressor p53: implications for tumor development and prognosis. J. Clin. Oncol. (1998) 16:3158-3168.
9. LIEBERMANN DA, HOFFMAN B, STEINMAN RA: Molecular controls of growth arrest and apoptosis: p53-dependent and independent markers. Oncogene (1995) 11:199-210.
10. DEPPERT W, GOHLER T, KOGA H, KIM E: Mutant p53: "gain of function" through perturbation of nuclear structure and function? J. Cell Biochem. Suppl. (2000) 35:115-122.
11. MOORE PS, SIPOS B, ORLANDINI S et al.: Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/ Smad4. Virc. Arch. (2001) 439:798-802.
12. NAKA, KOBAYASHI M, ASHIDA K et al.: Aberrant p16INK4 expression related to clinical stage and prognosis in patients with pancreatic cancer. Int. J. Oncol. (1998) 125:1111-1116.
13. NIO Y, DONG M, UEGAKI K et al.: Comparative significance of p53 and WAF/1-p21 expression on the efficacy of adjuvant chemotherapy for resectable invasive ductal carcinoma of the pancreas. Pancreas (1999) 18(2):117-126.
14. DIGIUSEPPE A, HRUBAN RH, GOODMAN SN et al.: Overexpression of p53 protein in adenocarcinoma of the pancreas. Am. J. Clin. Pathol. (1994) 101:684-688.
15. MAKINEN K, HAKALA T, LIPPONEN P et al.: Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res. (1998) 18:615-618.
16. NIO Y, DONG M, IGUCHI C et al.: Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J. Surg. Oncol. (2001) 76:188-196.
17. DERGHAM T, DUGAN MC, KUCWAY R et al.: Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int. J. Pancreatol. (1997) 21(2):127-143.
18. KAWESHA A, GHANEH P, ANDREN-SANDBERG A et al.: K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int. J. Cancer (2000) 89(6):469-474.
19. CAMPANI D, BOGGI U, CECCHETTI D et al.: p53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer. Pancreas (1999) 19:26-32.
20. YOKOYAMA M, YAMANAKA Y, FRIESS H et al.: p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res. (1994) 14(6B):2477-2483.
21. HU YX, WATANABE H, OHTSUBO K et al.: Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma. Br. J. Cancer (1999) 80:1075-1079.
22. ZHANG Y, RUGGERI B, AGARWAL P et al.: Immunohistochemical analysis of p53 expression in human pancreatic carcinomas. Arch. Pathol. Lab. Med. (1994) 1182:150-154.
23. DONG M, NIO Y, TAMURA K et al.: Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese and Western patients. Cancer Epidemiol. Biomark. Prev. (2000) 9:279-284.
24. DONG M, NIO Y, YAMASAWA K et al.: p53 alteration is not an independent prognostic indicator, but affects the efficacy of adjuvant chemotherapy in human pancreatic cancer. J. Surg. Oncol. (2003) 82:111-120.
25. RUGGERI BA, HUANG L, BERGER D et al.: Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer (1997) 79(4):700-716.
26. SINICROPE FA, EVANS DB, LEACH SD et al.: Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin. Cancer Res. (1996) 2(12):2015-2022.
27. NAKAMORI S, YASHIMA K, MURAKAMI Y et al.: Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn J. Cancer Res. (1995) 86(2):174-181.
28. LUNDIN J, NORDLING S, VON BOGUSLAWSKY K et al.: Prognostic value of immunohistochemical expression of p53 in patients with pancreatic cancer. Oncology (1996) 52(2):104-111.
29. LIGGETT WH, SIDRANSKY D: Role of the p16 tumour suppressor gene in cancer. J. Clin. Oncol. (1998) 16:1197-1203.
30. ROZENBLUM E, SCHUTTE M, GOGGINS M et al.: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. (1997) 57:1731-1734.
31. GERDES B, RAMASWAMY A, ZIEGLER A et al.: p16INK4a is a prognostic marker in resected ductal pancreatic cancer: an analysis of p16INK4a, p53, MDM2, an Rb. Ann. Surg. (2002) 235(1):51-59.
32. BLANKIN AV, MOREY AL, LEE C et al.: DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J. Clin. Oncol. (2002) 20:4531-4542.
33. HU YX, WATANABE H, OHTSUBO K et al.: Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. Clin. Cancer Res. (1997) 3(9):1473-1477.
34. OHTSUBO K, WATANABE H, YAMAGUCHI Y et al.: Abnormalities of tumor suppressor gene p16 in pancreatic carcinoma immunohistochemical and genetic findings compared with clinicopathological parameters. J. Gastroenterol. (2003) 38(7):663-671.
35. JEONG J, PARK YN, PARK JS, YOON DS, CHI HS, KIM BR: Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med. J. (2005) 46(4):519-525.
36. MASSAGUE J, BLAIN SW, LO RS: TGF-β signalling in growth control, cancer, and heritable disorders. Cell (2000) 103:295-309.
37. HAHN SA, SCHUTTE M, HOQUE AT et al.: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 271(5247):350-353.
38. TANG H, ZOU SQ, HAO YH et al.: The relationship between loss expression of DPC4/Smad4 gene and carcinogenesis of pancreatobiliary carcinoma. Hepatobiliary Pancreat. Dis. Int. (2002) 1(4):624-629.
39. HUA Z, ZHANG YC, HU XM, JIA ZG: Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J. Gastroenterol. (2003) 9:2764-2767.
40. TASCILAR M, SKINNER HG, ROSTY C et al.: The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin. Cancer Res. (2001) 7:4115-4121.
41. BARBACID M: Ras genes. Annu. Rev. Biochem. (1987) 56:779-827.
42. SHERR CJ: The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. (2000) 60(14):3689-3695.
43. GRUNEWALD K LYONS J, FROHLICH A et al.: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int. J. Cancer (1989) 43:1037-1041.
44. DERGHAM ST, DUGAN MC, KUCWAY R et al.: Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int. J. Pancreatol. (1997) 21(2):127-143.
45. SONG MM, NIO Y, DONG M et al.: Comparison of K-ras mutation at codon 12 and p21 expression in pancreatic cancer between Japanese and Chinese patients. J. Surg. Oncol. (2000) 75:176-185.
46. SONG MM, NIO Y, SATO Y et al.: Clinicopathological significance of K-ras point mutation and expression in benign and malignant exocrine turnouts of the human pancreas. Int. J. Pancreatol. (1996) 20:85-93.
47. ALLISON DC, PIANTADOSI S, HRUBAN RH et al.: DNA content and other factors associated with 10-year survival after resection of pancreatic carcinoma. J. Surg. Oncol. (1998) 6:151-159.
48. KITAGO M, UEDA M, AIRURA K et al.: Comparison of K-ras mutation distributions in intraductal papillary mucinous turnouts and ductal adenocarcinoma of the pancreas. Intl. J. Cancer (2004) 10:177-182.
49. MOTOJIMA K, URANO T, NAGATA Y et al.: Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumour stage in human pancreatic carcinoma. Am. J. Gastroenterol. (1991) 86:1784-1788.
50. FINKELSTEIN SD, PRZYGODZKI RM, PRICOLO VE et al.: K-ras-2 topographic genotyping of pancreatic adenocarcinoma. Arch. Surg. (1994) 129:367-372.
51. HRUBAN RH, VAN MANSFIELD AD, OFFERHAUS G et al.: K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant enriched chain reaction analysis and allele specific oligonucleotide hybridization. Am. J. Pathol. (1993) 143:545-554.
52. JUUTI A, NORDLING S, LOUHIMO J et al.: Loss of p27 expression is associated with poor prognosis in stage I-II pancreatic cancer. Oncology (2003) 65:371-377.
53. LU CD, MORITA S, ISHIBASHI T et al.: Loss of p27-kip1 expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer (1999) 85:1250-1260.
54. FU M, WANG C, LI Z, SAKAMAKI T, PESTELL RG: Minireview cyclin D1: normal and abnormal functions. Endocrinology (2004) 145(12):5439-5447.
55. LI YJ, JI XR: Relationship between the expression of β-catenin, cyclin D1 and myc and the occurrence and biological behaviour of pancreatic cancer. Zhonghua Bing Li Xue Za Zhi (2003) 32:238-241.
56. QIAO Q, RAMADANI M, GANSAUGE S et al.: Reduced membranous and ectopic cytoplasmic expression of β-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer. Int. J. Cancer (2001) 95:194-197.
57. GANSAUGE F, GANSAUGE S, SCHMIDT E et al.: Prognostic significance of molecular alterations in human pancreatic carcinoma an immunological study. Langebecks Arch. Surg. (1998) 383:152-155.
58. KAWESHA A, GHANEH P, ANDREN-SANDBERG A et al.: K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int. J. Cancer (2000) 89(6):469-474.
59. KORNMANN M, ISHIWATA T, ITAKURA J et al.: Increased cyclin D1 in human pancreatic cancer is associated with decreased postoperative survival. Oncology (1998) 55(4):363-369.
60. GANSAUGE S, GANSUAGE F, RAMADANI M et al.: Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. (1997) 57:1634-1637.
61. JACOBSON MD, WEIL M, RAFF MC: Programmed cell death in animal development. Cell (1997) 88:347-354.
62. ASHKENAZI A, DIXIT VM: Death receptors: signaling and modulation. Science (1998) 281:1305-1308.
63. GREEN DR, REED JC: Mitochondria and apoptosis. Science (1998) 281:1309-1312.
64. BURLACU A: Regulation of apoptosis by Bcl-2 family proteins. J. Cell Mol. Med. (2003) 7(3):249-257.
65. SUN CY, WANG BL, HU CQ et al.: Expression of the bcl-2 gene and its significance in human pancreatic cancer. Hepatobiliary Pancreat. Dis. Int. (2002) 1:306-308.
66. NIO Y, IGUCHI C, YAMASAWA K et al.: Apoptosis and expression of Bcl-2 and Bax proteins in invasive ductal carcinoma of the pancreas. Pancreas (2001) 22:230-239.
67. NIO Y, DONG M, IGUCHI C et al.: Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: effects on clinical outcome and efficacy of adjuvant chemotherapy. J. Surg. Oncol. (2001) 76:188-196.
68. EVANS JD, CORNFORD PA, DODSON A et al.: Detailed tissue expression of bcl-2, bax, bak and bcl-x in the normal human pancreas and chronic pancreatitis, ampullary and pancreatic ductal adenocarcinomas. Pancreatology (2001) 1:254-262.
69. HU YX, WATANABE H, OHTSUBO K et al.: Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma. Br. J. Cancer (1999) 80:1075-1079.
70. FRIESS H, LU Z, GRABER HU et al.: Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut (1998) 43:414-421.
71. FRIESS H, LU Z, ANDREN-SANDBERG A et al.: Moderate activation of the apoptosis inhibitor bcl-xL worsens prognosis in pancreatic cancer. Ann. Surg. (1998) 228:780-787.
72. OHSHIO G, SUWA H, IMMAMURA T et al.: An immunohistochemical study of blc-2 and p53 protein expression in pancreatic carcinomas. Scand. J. Gastroenterol. (1998) 33:535-539.
73. MAKINEN K, HAKALA T, LIPPONEN P et al.: Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res. (1998) 18:615-618.
74. SINICROPE FA, EVANS DB, LEACH SD et al.: Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin. Cancer Res. (1996) 2(12):2015-2022.
75. DONG M, ZHOU JP, ZHANG H, GUO KJ, TIAN YL, DONG YT: Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer. World J. Gastroenterol. (2005) 11(18):2744-2747.
76. MAGISTRELLI P, COPPOLA R, TONINI G et al.: Apoptotic index or a combination of Bax/Bcl-2 expression correlate with survival after resection of pancreatic adenocarcinoma. J. Cell Biochem. (2006) 97(1):98-108.
77. CROW MT: Hypoxia. BNip3 proteins, and the mitochondrialdeath pathway in cardiomyocytes. Circ. Res. (2002) 91:183-185.
78. ERKAN M, KLEEFF J, ESPOSITO I et al.: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene (2005) 24(27):4421-4432.
79. LACASSE EC, BAIRD S, KORNELUK RG, MACKENZIE AE: The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene (1998) 17:3247-3259.
80. KAMI K, DOI R, KOIZUMA M et al.: Survivin expression is a prognostic marker in pancreatic cancer patients. Surgery (2004) 136:443-448.
81. TONINI G, VINCENZI B, SANTINI D et al.: Nuclear and cytoplasmic expression of survivin in 67 surgically resected pancreatic cancer patients. Br. J. Cancer (2005) 92(12):2225-2232.
82. LIOTTA LA, RAO CN, BARSKY SH: Tumor invasion and the extracellular matrix. Lab. Invest. (1983) 49:636-649.
83. LAFLAMME SE, AUER KL: Integrin signalling. Semin. Cancer Biol. (1996) 7:111-118.
84. FRISCH SM, RUOSLAHTI E: Integrin and anoikis. Curr. Opin. Cell Biol. (1997) 9(5):701-707.
85. VARGHESE S: Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions. Front. Biosci. (2006) 11:2949-2966.
86. HARVEY SR, HURD TC, MARKUS G et al.: Evaluation of urinary plasminogen activator, its receptor matrix metalloproteinase-9 and von Willebrand factor in pancreatic cancer. Clin. Cancer Res. (2003) 9(13):4935-4943.
87. NAKAMURA H, HORITA S, SENMARU N et al.: Association of matrilysin expression with progression and poor prognosis in human pancreatic adenocarcinoma. Oncol. Rep. (2002) 9:751-755.
88. YAMMAMOTO H, ITAH F, IKU S et al.: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J. Clin. Oncol. (2001) 19:1118-1127.
89. MAATA M, SOINI Y, LIAKKA A et al.: Differential expression of matrix metalloproteinase (MMP)-2 and 9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumour progression and clinical prognosis. Clin. Cancer Res. (2000) 6:2726-2734.
90. GONG YL, XU GM, HUANG WD et al.: Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. J. Surg. Oncol. (2000) 73:95-99.
91. ITO T, ITO M, SHIOZAWA J et al.: Expression of MMP-1 in human pancreatic carcinoma: relationship with prognostic factors. Mod. Pathol. (1999) 12:669-674.
92. KOSHIBA T, HOSOTANI R, WADA M et al.: Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer (1998) 82:642-650.
93. JONES LE, HUMPHREYS MJ, CAMPBELL F, NEOPTOLEMOS JP, BOYD MT: Comprehensive analysis of matrix metalloproteinase and tissue inhibitor expression in pancreatic cancer increased expression of matrix metalloproteinase-7 predicts poor survival. Clin. Cancer Res. (2004) 10(8):2832-2845.
94. GRUTZMANN R, LUTTGES J, SIPOS B et al.: ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br. J. Cancer (2004) 90(5):1053-1058.
95. IKEDA N, NAKAJIMA Y, TOKUHARA T et al.: Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin. Cancer Res. (2003) 9(4):1503-1508.
96. SHIMAMURA T, SAKAMOTO M: Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to E-cadherin expression. J. Clin. Oncol. (2003) 21(4):659-667.
97. BEAUVAIS DM, RAPRAEGER AC: Syndecans in tumor cell adhesion and signaling. Reprod. Biol. Endocrinol. (2004) 2:3.
98. JUUTI A, NORDLING S, LUNDIN J, LOUHIMO J, HAGLUND C: Syndecan-1 expression - a novel prognostic marker in pancreatic cancer. Oncology (2005) 68(2-3):97-106.
99. BORNSTEIN P, AGAH A, KYRIAKIDES TR: The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int. J. Biochem. Cell Biol. (2004) 36(6):1115-1125.
100. TOBITA K, KIJIMA H, DOWAKI S et al.: Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma. Int. J. Oncol. (2002) 21(6)1189-1195.
101. SAITOU M, GOTO M, HORINOUCHI M et al.: MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J. Clin. Pathol. (2005) 58(8):845-852.
102. MASUI T, DOI R, KOSHIBA T et al.: RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. Clin. Cancer Res. (2003) 9(5):1779-1784.
103. UEHARA H, MIYAMOTO M, KATO K et al.: Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res. (2004) 64:3533-3537.
104. NITORI N, INO Y: Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma. Clin. Cancer Res. (2005) 11:2531-2539.
105. SHIMAMURA T, SAKAMOTO M: Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin. Cancer Res. (2002) 8:2570-2575.
106. GUAN UL: The mitogen activated protein kinase signal transduction pathway: from the cell surface to the nucleus. Cell Signal. (1994) 6:581-589.
107. HILL CS, TREISMAN R: Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell (1995) 80:199-211.
108. ITOH S, ITOH F, GOUMANS MJ, TEN DIJKE P: Signaling of transforming growth factor-β family members through Smad proteins. Eur. J. Biochem. (2000) 267(24):6954-6967.
109. FRIESS H, BERBERAT P, SCHILLING M, KUNZ J, KORC M, BUCHLER MW: Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J. Mol. Med. (1996) 74:35-42.
110. LAKSHMIKESARI A, RADHAKRISHNA R, BRANUMATHI A et al.: Expression of epidermal and transforming growth factors in pancreatic cancer. Oncol. Rep. (1996) 3:963-966.
111. HASHIMOTO Y, NIO Y, SUMI S et al.: Correlation between TGF-β1 and p21 (WAFI/CIP1) expression and prognosis in resectable invasive ductal carcinoma of the pancreas. Pancreas (2001) 22:341-371.
112. WAGNER M, KLEEFF J, FRIESS H et al.: Enhanced expression of the type II TGF-β1 receptor is associated with decreased survival in human pancreatic cancer. Pancreas (1999) 19:370-376.
113. COPPOLA D, LU L, FREHAUF JP et al.: Analysis of p53, p21WAF1, and TGF-β1 in human ductal adenocarcinoma of the pancreas: TGF-β1 protein expression predicts longer survival. Am. J. Clin. Pathol. (1998) 110:16-23.
114. FRIESS H, YAMANAKA Y, BUCHLER M et al.: Enhanced expression of TGF-β isoform-2 in pancreatic cancer correlates with decreased survival. Gastroenterology (1993) 105:1846-1856.
115. OZAWA F, FRIESS H, TEMPIA-CALIERA A, KLEEFF J, BUCHLER MW: Growth factors and their receptors in pancreatic cancer. Teratog. Carcinog. Mutag. (2001) 21(1):27-44.
116. YAMANAKA Y, FRIESS H, KOBRIN MS et al.: Co-expression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumour aggressiveness. Anticancer Res. (1993) 13:565-570.
117. UEGAKI K, NIO Y, INOUE S et al.: Clinicopathological significance of epidermal growth factor and receptor in human pancreatic cancer. Anticancer Res. (1997) 17:3841-3847.
118. YAMANAKA Y: The immunohistochemical expressions of epidermal growth factor, epidermal growth factor receptors and c-erbB2 oncoprotein in human pancreatic cancer. Nippon Ika Daigaku Zasshi (1992) 59:51-61.
119. YAMANAKA Y, FRIESS H, KOBRIN MS et al.: Co-expression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumour aggressiveness. Anticancer Res. (1993) 13:565-570.
120. UEDA M, OGATA S, TSUDA H et al.: The correlation between cytoplasmic overexpression of epidermal growth factor and tumour aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas (2004) 29:1-8.
121. TAMIOLAKIS D, VENIZELOS I, SIMOPOULOS C et al.: Correlation of immunohistochemically detected HER-2/neu (erbB-2) with histological stage and perineural invasion in pancreatic cancer. Hepatogastroenterology (2004) 51:334-337.
122. TOBITA K, KIJIMA H, DOWAKI S et al.: Epidermal growth factor expression in human pancreatic carcinoma significance for liver metastasis. Int. J. Mol. Med. (2003) 11:305-309.
123. ZHANG H, YUAN SZ: Expression of c-erbB2 oncogene protein, epidermal growth factor receptor and TGF-β1 in human pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat. Dis. Int. (2002) 1:620-623.
124. KOKA V, POTTI A, KOCH M et al.: Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression of pancreatic carcinoma. Anticancer Res. (2002) 22:1593-1597.
125. THYBUSCH-BERNHARDT, BECKMANN S, JUHL H: Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumour stage. Int. J. Surg. Invest. (2001) 2:393-400.
126. SAFRAN H, STEINHOFF M, MANGRAY S et al.: Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am. J. Clin. Oncol. (2001) 24:496-499.
127. NOVOTNY J, PETRUZELKA L, VEDRALOVA J et al.: Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. Neoplasma (2001) 48:188-191.
128. GRABER HU, FRIESS H, KAUFMANN B et al.: ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. Int. J. Cancer (1999) 84:24-27.
129. DUGAN MC, DERGHAM ST, KUCWAY R et al.: HER-2/neu expression in pancreatic adenocarcinoma: relationship to tumour differentiation and survival. Pancreas (1997) 14:229-236.
130. OKADA N, OHSHIO G, YAMAKI K et al.: Elevated serum c-erbB-2 protein levels in patients with pancreatic cancer: correlation to metastasis and shorter survival. Oncology (1995) 52(5):392-396.
131. LEI S, APPERT HE, NAKATA B et al.: Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int. J. Pancreatol. (1995) 17:15-21.
132. BYRNE AM, BOUCHIER-HAYES DJ, HARMEY JH: Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J. Cell Mol. Med. (2005) 9(4):777-794.
133. KURAHARA H, TAKAO S, MAEMURA K, SHINCHI H, NATSUGOE S, AIKOU T: Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin. Cancer Res. (2004) 10(24):8413-8412.
134. BUCHLER P, REBER HA, BUCHLER MW et al.: VEGF-RII influences the prognosis of pancreatic cancer. Ann. Surg. (2002) 236:738-749.
135. NIEDERGETHMANN M, HILDENBRAND R, WOSTBROCK B et al.: High expression of vascular endothelial growth factor predicting early recurrence and poor prognosis after curative resection of ductal adenocarcinoma of the pancreas. Pancreas (2002) 25:122-129.
136. SEO Y, BABA H, FUKUDA T et al.: High expression of vascular endothelial growth factor is associated with liver metastasis and poor prognosis for patients with ductal adenocarcinoma. Cancer (2000) 88:2239-2245.
137. IKEDA N, ADACHI M, TAKI T et al.: Prognostic significance of angiogenesis in human pancreatic cancer. Br. J. Cancer (1999) 79:1553-1563.
138. MACDONALD PM, STRUHL G: A molecular gradient in early Drosophila embryos and its role in specifying the body pattern. Nature (1986) 324:537-545.
139. SUH E, CHEN L, TAYLOR J, TRABER PG: A homeodomain protein related to caudal regulates intestine-specific gene transcription. Mol. Cell Biol. (1994) 14:7340-7351.
140. DRUMMOND F, PUTT W, FOX M, EDWARDS YH: Cloning and chromosome assignment of the human CDX2 gene. Ann. Hum. Genet. (1997) 61(5):393-400.
141. MATSUMOTO K, MIZOSHITA T, TSUKAMOTO T: Cdx2 expression in pancreatic tumors: relationship with prognosis of invasiveductal carcinomas. Oncol. Rep. (2004) 12(6):1239-1243.
142. KIM J, REBER HA, HINES OJ et al.: The clinical significance of MAGEA3 expression in pancreatic cancer. Int. J. Cancer (2006) 118(9):2269-2275.
143. ENJOJI M, NAKASHIMA M, YAMAGUCHI K, KOTOH K, NAKAMUTA M: Significance of RCAS1 antigen in hepatocellular, cholangiocellular and pancreatic carcinomas. J. Gastroenterol. Hepatol. (2005) (8):1143-1148.
144. HIRAOKA K, HIDA Y, MIYAMOTO M et al.: High expression of tumor-associated antigen RCAS1 in pancreatic ductaladenocarcinoma is an unfavorable prognostic marker. Int. J. Cancer (2002) 99(3):418-423.
145. JI P, GOLDIN L, REN H et al.: SKP2 contains a novel cyclin a binding domain that directly protects cyclin A from inhibition by p27Kip1. J. Biol. Chem. (2006) 281(33):24058-24069.
146. EINAMA T, KAGATA Y, TSUDA H et al.: High-level Skp2 expression in pancreatic ductal adenocarcinoma correlationwith the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas (2006) 32(4):376-381.
147. SHIBAJI T, NAGAO M, IKEDA N et al.: Prognostic significance of HIF-1α overexpression in human pancreaticcancer. Anticancer Res. (2003) 23(6C):4721-4727.
148. TEZEL E, HIBI K, NAGASAKA T, NAKAO A: PGP9.5 as a prognostic factor in pancreatic cancer. Clin. Cancer Res. (2000) 6(12):4764-4767.
149. VIMALACHANDRAN D, GREENHALF W, THOMPSON C et al.: High nuclear S100A6 (calcyclin) is significantly associated with poor survivalin pancreatic cancer patients. Cancer Res. (2005) 65(8):3218-3225.
150. SONG G, OUYANG G, BAO S: The activation of Akt/PKB signaling pathway and cell survival. J. Cell Mol. Med. (2005) 9(1):59-71.
151. YAMAMOTO S, TOMITA Y, HOSHIDA Y et al.: Prognostic significance of activated Akt expression in pancreatic ductaladenocarcinoma. Clin. Cancer Res. (2004) 10(8):2846-2850.
152. SUZUOKI M, MIYAMOTO M, KATO K et al.: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br. J. Cancer (2002) 87(10):1140-1144.
153. GOTTESMAN MM, FOJO T, BATES SE: Multidrug resistance in cancer: rote of ATP-dependent transporters. Nat. Rev. Cancer (2002) 2:48-58.
154. LU Z, KLEEFF J, SHRIKHANDE S et al.: Expression of the multidrug-resistance 1 (MDR1) gene and prognosis in human pancreatic cancer. Pancreas (2000) 21(3):240-247.
155. SUWA H, OHSHIO G, ARAO S et al.: Immunohistochemical localization of P-glycoprotein and expression of the multidrug resistance-1 gene in human pancreatic cancer: relevance to indicator of better prognosis. Jpn J. Cancer Res. (1996) 87(6):641-649.
156. MACDONALD JS, MCCOY S, WHITEHEAD RP et al.: A Phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study. Invest. New Drugs (2005) 23:485-487.
157. HEZEL AF, KIMMELMAN AC, STANGER BZ, BARDEESY N, DEPINHO RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. (2006) 20:1218-1249.
158. XIONG HQ: Molecular targeting therapy for pancreatic cancer. Cancer Chemother. Pharmacol. (2004) 54(Suppl. 1):S69-S77.
159. BRAMHALL SR, ROSEMURGY A, BROWN PD et al.: Marimastat as first-line therapy for patients with unresectable pancreatic cancer; a randomized trial. J. Clin. Oncol. (2001) 19:3447-3455.
160. BRAMHALL SR, SCHULZ J, NEMUNAITIS J et al.: A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer (2002) 87:161-167.
161. MOORE MJ, GOLDSTEIN D, HAMM J et al.: Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: a Phase III trial of the National cancer institute of Canada Clinical trials group (NCIC-CTG). Program and Abstracts of the 2005 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (27-29 January 2005), Hollywood, Florida, USA (2005):(Abstract 77).
162. WACKER B, NAGRANI T, WEINBERG J, WITT K, CLARK G, CAGNONI PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large Phase III studies. Clin. Cancer Res. (2007) 13(13):3913-3921.
163. SINGH A, MONIAUX, N, CHAUHAN S et al.: Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. (2004) 64:622-630.
164. SINGH AP, CHATURVEDI P, BATRA SK: Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res. (2007) 67:433-436.
165. KINDLER HL, NIEDZWIECKI D, HOLLIS D et al.: A double-blind, placebo-controlled, randomized Phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of cancer and leukemia group B (CALGB) 80303. Program and Abstracts of the 2007 American Society of Clinical Oncology Gastrointestinal Cancers Symsposium (17-21 January 2007), Orlando, Florida, USA (2007):(Abstract 108).